𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer

✍ Scribed by Geoffrey Falkson; Hèndré C. Falkson

Publisher
Springer
Year
1983
Tongue
English
Weight
215 KB
Volume
11
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high-dose MPA well. Side-effects were minimal and reversible. The commonest side-effects were tremor or edema. The CR plus PR rate was five of 23 (22%). All responding patients were over 50 years of age and had a good performance status. Hormone receptor status was known in four patients only, so that no correlation between receptor status and response could be drawn. MPA appears to be a useful hormone for use in the management of breast cancer. Optimal dosage remains to be determined.

📜 SIMILAR VOLUMES

Medroxyprogesterone acetate bioavailabil
Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer
✍ Carlo M. Camaggi; Elena Strocchi; Barbara Costanti; Paola Beghelli; Patrizio Fer 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 273 KB

Administration of medroxyprogesterone acetate IP in advanced cancer with peritoneal metastases and ascitic effusion generates considerably higher drug plasma levels than those observed after PO or IM treatment. Comparison of areas under the time-concentration curves (AUC) with reference to the three

Adrenal suppression by oral high-dose me
Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients
✍ Henk Veelen; Pax H. B. Willemse; Dirk T. Sleijfer; John J. Pratt; Wim J. Sluiter 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 332 KB

The effects of oral MPA, 300 mg t.i.d., on adrenal function in postmenopausal patients with disseminated breast cancer were evaluated. The levels of serum cortisol, ACTH, androstenedione, DHEA-S, LH, FSH, GH, and prolactin in 22 patients receiving MPA were compared with those in another group of 28

Mechanism of adrenal suppression by high
Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients
✍ H. Veelen; P. H. B. Willemse; D. T. Sleijfer; E. Ploeg; W. J. Sluiter; H. Dooren 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 362 KB

To investigate the mechanism of adrenal suppression by high-dose MPA, we performed direct and indirect stimulation tests in postmenopausal women with disseminated breast cancer who were receiving MPA and in a postmenopausal breast cancer control group. A partial adrenal insufficiency was found durin